Alex Thompson
Stock Analyst at Stifel
(1.62)
# 3,267
Out of 4,924 analysts
34
Total ratings
46.43%
Success rate
-8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics | Reinstates: Buy | $22 | $7.90 | +178.48% | 1 | Jun 11, 2025 | |
| KYMR Kymera Therapeutics | Reinstates: Buy | $55 | $41.32 | +33.12% | 1 | May 20, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $22 → $23 | $17.24 | +33.41% | 3 | May 2, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $8.30 | +334.00% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $28.53 | +110.30% | 1 | Mar 25, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $200 → $207 | $182.60 | +13.36% | 2 | Nov 15, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $14.25 | +243.86% | 1 | Oct 11, 2024 | |
| ARGX argenx SE | Maintains: Buy | $485 → $500 | $673.15 | -25.72% | 4 | Jun 24, 2024 | |
| SYRE Spyre Therapeutics | Reiterates: Buy | $36 → $54 | $15.93 | +238.98% | 2 | Mar 26, 2024 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | $44 | $20.39 | +115.79% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $2 | $2.53 | -20.95% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $52.76 | +30.78% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $1.55 | -35.48% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $17.20 | +132.56% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $9.99 | +3,103.20% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $15.96 | +113.03% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.69 | +1,852.66% | 1 | Dec 14, 2022 |
Cullinan Therapeutics
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $7.90
Upside: +178.48%
Kymera Therapeutics
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $41.32
Upside: +33.12%
Travere Therapeutics
May 2, 2025
Maintains: Hold
Price Target: $22 → $23
Current: $17.24
Upside: +33.41%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $8.30
Upside: +334.00%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $28.53
Upside: +110.30%
Ascendis Pharma
Nov 15, 2024
Maintains: Buy
Price Target: $200 → $207
Current: $182.60
Upside: +13.36%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $14.25
Upside: +243.86%
argenx SE
Jun 24, 2024
Maintains: Buy
Price Target: $485 → $500
Current: $673.15
Upside: -25.72%
Spyre Therapeutics
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $15.93
Upside: +238.98%
Dianthus Therapeutics
Feb 15, 2024
Initiates: Buy
Price Target: $44
Current: $20.39
Upside: +115.79%
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $2.53
Upside: -20.95%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $52.76
Upside: +30.78%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $1.55
Upside: -35.48%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $17.20
Upside: +132.56%
Aug 9, 2023
Initiates: Buy
Price Target: $320
Current: $9.99
Upside: +3,103.20%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $15.96
Upside: +113.03%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.69
Upside: +1,852.66%